Abstract
Interest in the use of fluid biomarkers for monitoring disease course in multiple sclerosis is growing. Neurofilaments are structural proteins, and neurofilament light chain (NfL) is released after neuroaxonal injury. 1 Gafson AR Barthélemy NR Bomont P et al. Neurofilaments: neurobiological foundations for biomarker applications. Brain. 2020; 143: 1975-1998 Google Scholar NfL can be measured in blood by ultrasensitive assays, with good correlation between blood and CSF levels. 1 Gafson AR Barthélemy NR Bomont P et al. Neurofilaments: neurobiological foundations for biomarker applications. Brain. 2020; 143: 1975-1998 Google Scholar , 2 Kuhle J Barro C Andreasson U et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. ClinChemLab Med. 2016; 54: 1655-1661 Google Scholar Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation studyThe use of sNfL percentiles and Z scores allows for identification of individual people with multiple sclerosis at risk for a detrimental disease course and suboptimal therapy response beyond clinical and MRI measures, specifically in people with disease activity-free status. Additionally, sNfL might be used as an endpoint for comparing effectiveness across drug classes in pragmatic trials. Full-Text PDF
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
